Kyverna Therapeutics, Inc. (NASDAQ:KYTX) Receives Consensus Rating of “Moderate Buy” from Analysts

Kyverna Therapeutics, Inc. (NASDAQ:KYTX) has been assigned an average recommendation of “Moderate Buy” from the six research firms that are presently covering the company, Marketbeat reports. One investment analyst has rated the stock with a sell recommendation and five have assigned a buy recommendation to the company. The average 12-month price objective among brokerages that have covered the stock in the last year is $30.00.

KYTX has been the subject of a number of analyst reports. HC Wainwright reaffirmed a “buy” rating and set a $25.00 price objective on shares of Kyverna Therapeutics in a research note on Wednesday, June 3rd. Wall Street Zen cut Kyverna Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, May 30th. JPMorgan Chase & Co. reduced their target price on Kyverna Therapeutics from $30.00 to $29.00 and set an “overweight” rating on the stock in a report on Wednesday, May 13th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Kyverna Therapeutics in a research report on Wednesday, June 24th.

Institutional Inflows and Outflows

A number of institutional investors have recently bought and sold shares of KYTX. Phoenix Wealth Advisors boosted its position in Kyverna Therapeutics by 17.1% during the 4th quarter. Phoenix Wealth Advisors now owns 12,300 shares of the company’s stock worth $116,000 after acquiring an additional 1,800 shares during the last quarter. Public Employees Retirement System of Ohio bought a new position in shares of Kyverna Therapeutics during the 3rd quarter worth approximately $28,000. Federated Hermes Inc. raised its holdings in shares of Kyverna Therapeutics by 36.6% in the fourth quarter. Federated Hermes Inc. now owns 20,705 shares of the company’s stock valued at $195,000 after purchasing an additional 5,547 shares during the last quarter. Rhumbline Advisers raised its holdings in shares of Kyverna Therapeutics by 22.0% in the first quarter. Rhumbline Advisers now owns 31,614 shares of the company’s stock valued at $61,000 after purchasing an additional 5,694 shares during the last quarter. Finally, Bank of America Corp DE lifted its position in shares of Kyverna Therapeutics by 41.6% in the fourth quarter. Bank of America Corp DE now owns 21,788 shares of the company’s stock worth $81,000 after purchasing an additional 6,400 shares in the last quarter. Institutional investors and hedge funds own 18.08% of the company’s stock.

Kyverna Therapeutics Price Performance

KYTX opened at $7.45 on Monday. The company has a fifty day moving average price of $8.56 and a two-hundred day moving average price of $8.60. The firm has a market capitalization of $452.89 million, a PE ratio of -2.27 and a beta of 1.87. Kyverna Therapeutics has a 52 week low of $2.80 and a 52 week high of $13.67. The company has a debt-to-equity ratio of 0.13, a quick ratio of 8.15 and a current ratio of 8.15.

Kyverna Therapeutics (NASDAQ:KYTX) last posted its quarterly earnings results on Tuesday, May 12th. The company reported ($0.66) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.75) by $0.09. As a group, analysts anticipate that Kyverna Therapeutics will post -2.78 earnings per share for the current year.

About Kyverna Therapeutics

Kyverna Therapeutics is a clinical‐stage biotechnology company dedicated to developing engineered regulatory T‐cell (Treg) therapies for the treatment of autoimmune and inflammatory diseases. Leveraging a proprietary platform for the isolation, expansion and modification of Treg cells, the company aims to restore immune homeostasis in patients by delivering antigen‐specific cell therapies that selectively target diseased tissues while minimizing systemic immunosuppression.

The company’s lead programs include an allogeneic Treg candidate in clinical development for ulcerative colitis, with additional preclinical assets focused on rheumatoid arthritis and other chronic inflammatory conditions.